Menopause Inflammation Markers Linked to Cognitive Aging in Women

Introduction: Midlife Inflammation May Shape Cognitive Aging in Women

Two inflammatory and immune markers measured during the menopause transition — glycoprotein acetyls (GlycA) and complement factor C3 — tracked with later cognitive performance in a longitudinal study of 503 midlife women. The findings point to a biological window during which the body’s shifting immune environment, rather than estrogen loss alone, may influence memory and thinking speed decades before dementia appears.

GlycA and Complement: How Immune Signals Measured in Midlife Predict Later Cognition

Researchers led by Meng Qi and Samar El Khoudary at Virginia Commonwealth University, working with the multi-site Study of Women’s Health Across the Nation (SWAN) HDL Ancillary Study team, measured serum GlycA, complement C3, and C4 repeatedly over an average of 6.1 years in 503 midlife women, generating 1,234 observations. Cognitive tests — working memory, processing speed, and episodic memory, including immediate and delayed recall — were administered roughly 1.5 years later. Using joint models that link biomarker trajectories over time to later test performance, the team could ask whether immune activity during the menopause transition foreshadows cognitive outcomes.

GlycA is a nuclear magnetic resonance-based marker that reflects the glycosylated carbohydrate chains on acute-phase proteins like alpha-1-acid glycoprotein and haptoglobin — essentially a readout of systemic low-grade inflammation. Complement factors C3 and C4 are core components of the innate immune system’s complement cascade. These proteins are not merely bystanders: activated complement fragments participate in synaptic pruning and neuroinflammation, and elevated C3 has been linked to amyloid pathology in Alzheimer’s disease research. Chronically elevated systemic inflammation can also damage the vascular endothelium that supplies the brain, a pathway explored in more detail in our article on insulin resistance and arterial stiffness after menopause.

Why does midlife matter? Estradiol normally exerts anti-inflammatory effects, suppressing NF-κB signaling and reducing production of interleukin-6 and other pro-inflammatory cytokines. As estradiol fluctuates and then falls during the transition, inflammatory markers tend to rise — creating the very immune environment this study captured. The design is a strength: by measuring biomarkers repeatedly rather than once, the researchers could model each woman’s inflammatory trajectory, not a single snapshot.

PCOS After Menopause: Symptoms Fade, Cognitive and Cardiometabolic Risks Don’t

A second body of evidence reframes how we think about lifelong endocrine health. In a September 2026 review in Fertility and Sterility, Emma HogenEsch and Dr. Heather Huddleston of the University of California, San Francisco describe polyendocrine metabolic ovarian syndrome (PMOS, formerly called PCOS) as a lifelong condition rather than one confined to the reproductive years. With age, menstrual cycles often become more regular, ovulation improves, ovarian morphology normalizes somewhat, and biochemical hyperandrogenism can soften. Paradoxically, this can make diagnosing PMOS in a woman’s 30s or 40s harder.

The symptom improvements are deceptive. Underlying metabolic dysfunction — insulin resistance, dyslipidemia, hypertension, and increased cardiovascular disease risk — persists into midlife and beyond, alongside elevated rates of depression and anxiety. Critically, the review also flags cognitive health implications: chronic hyperinsulinemia, visceral adiposity, and low-grade inflammation are each independently associated with accelerated cognitive decline, and women with PCOS carry these burdens for decades. The authors note a striking gap: longitudinal studies following women with PMOS past menopause remain rare, limiting what can be said about dementia risk specifically. This is honest uncertainty, not established fact.

What This Means for Your Brain: Mechanisms Worth Understanding

Connecting the two lines of research: the menopause transition creates a pro-inflammatory shift at precisely the moment when midlife women with metabolic disorders like PMOS already carry elevated inflammatory load. Complement activation and GlycA elevation may compound insulin resistance’s vascular effects on cerebral small vessels. Over years, this combination can erode processing speed and episodic memory — the domains SWAN measured — even when symptoms feel subtle or are dismissed as “brain fog.” For help distinguishing the two, see our guide on menopause brain fog versus dementia.

Practical Applications: Modifiable Targets During Midlife

• Manage insulin resistance aggressively in midlife — regular resistance exercise improves glucose handling and reduces systemic inflammation. Our piece on why muscle strength beats muscle mass after menopause covers protocols.
• Address sleep disruption — poor sleep elevates inflammatory markers; if night sweats are the cause, discuss options ranging from low-dose melatonin to non-hormonal treatments with your clinician.
• Ask about cardiometabolic screening — women with a PCOS history should ensure lipid panels, glucose or HbA1c, and blood pressure continue to be monitored after menopause, since symptoms fade while risks don’t.
• Consider anti-inflammatory nutrition — omega-3 fatty acids (EPA and DHA) from fish or supplements and a Mediterranean-style dietary pattern have the most consistent evidence for lowering GlycA-type systemic inflammation.

Frequently Asked Questions

Does menopause itself cause memory problems?

Menopause is associated with temporary declines in verbal memory and processing speed, but the SWAN findings suggest it’s the accompanying inflammatory and metabolic changes — not estrogen loss alone — that may carry longer-term cognitive implications.

What is GlycA and why does it matter for cognition?

GlycA is a blood marker of systemic low-grade inflammation, reflecting several acute-phase immune proteins. Elevated midlife GlycA predicted worse future cognitive test performance in the SWAN study.

I have PCOS and I’m approaching menopause — are my symptoms going away?

Menstrual and hormonal symptoms often improve with age, but UCSF researchers emphasize that metabolic and cardiovascular risks persist, so ongoing monitoring and preventive care remain important.

Can I lower inflammation that affects the brain?

Regular exercise, good sleep, omega-3-rich nutrition, and treating insulin resistance are the best-evidenced ways to reduce chronic systemic inflammation during midlife.

Conclusion

Longitudinal evidence now ties midlife immune activity — GlycA and complement C3 — to later cognitive performance in women, while reframing PCOS as a lifelong disorder with cognitive relevance. Both studies share a message: midlife is not a hormonal footnote but a decisive interval for brain health. Women with metabolic histories, and their clinicians, have concrete, modifiable targets.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42705588/
https://pubmed.ncbi.nlm.nih.gov/42549661/
https://pubmed.ncbi.nlm.nih.gov/42428989/
https://pubmed.ncbi.nlm.nih.gov/42364668/
https://pubmed.ncbi.nlm.nih.gov/42360361/